Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Immune Checkpoint Therapies in Prostate Cancer.

Goswami S, Aparicio A, Subudhi SK.

Cancer J. 2016 Mar-Apr;22(2):117-20. doi: 10.1097/PPO.0000000000000176.

PMID:
27111907
2.

A primer on tumour immunology and prostate cancer immunotherapy.

Ren R, Koti M, Hamilton T, Graham CH, Nayak JG, Singh J, Drachenberg DE, Siemens DR.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):60-5. doi: 10.5489/cuaj.3418. Review. No abstract available.

3.

A Model-Based Joint Identification of Differentially Expressed Genes and Phenotype-Associated Genes.

Cho SS, Kim Y, Yoon J, Seo M, Shin SK, Kwon EY, Kim SE, Bae YJ, Lee S, Sung MK, Choi MS, Park T.

PLoS One. 2016 Mar 10;11(3):e0149086. doi: 10.1371/journal.pone.0149086. eCollection 2016. Erratum in: PLoS One. 2016;11(4):e0153341.

4.

Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.

Foy SP, Sennino B, Dela Cruz T, Cote JJ, Gordon EJ, Kemp F, Xavier V, Franzusoff A, Rountree RB, Mandl SJ.

PLoS One. 2016 Feb 24;11(2):e0150084. doi: 10.1371/journal.pone.0150084. eCollection 2016.

5.

Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?

Van Brussel I, Van Craenenbroeck AH, Schrijvers DM, Cools N.

Transl Androl Urol. 2013 Jun;2(2):85-8. doi: 10.3978/j.issn.2223-4683.2012.10.02. No abstract available.

6.

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Wurz GT, Kao CJ, DeGregorio MW.

Ther Adv Med Oncol. 2016 Jan;8(1):4-31. doi: 10.1177/1758834015615514. Review.

7.

Engineered Materials for Cancer Immunotherapy.

Cheung AS, Mooney DJ.

Nano Today. 2015 Aug 1;10(4):511-531.

PMID:
26640511
8.

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

Turnbull S, West EJ, Scott KJ, Appleton E, Melcher A, Ralph C.

Viruses. 2015 Dec 2;7(12):6291-312. doi: 10.3390/v7122938. Review.

9.

The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance.

Hermann-Kleiter N, Klepsch V, Wallner S, Siegmund K, Klepsch S, Tuzlak S, Villunger A, Kaminski S, Pfeifhofer-Obermair C, Gruber T, Wolf D, Baier G.

Cell Rep. 2015 Sep 29;12(12):2072-85. doi: 10.1016/j.celrep.2015.08.035. Epub 2015 Sep 17.

10.

Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.

Martin SD, Coukos G, Holt RA, Nelson BH.

Ann Oncol. 2015 Dec;26(12):2367-74. doi: 10.1093/annonc/mdv382. Epub 2015 Sep 14. Review.

PMID:
26371284
11.

ABO blood type correlates with survival on prostate cancer vaccine therapy.

Muthana SM, Gulley JL, Hodge JW, Schlom J, Gildersleeve JC.

Oncotarget. 2015 Oct 13;6(31):32244-56. doi: 10.18632/oncotarget.4993.

12.

Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

Obeid J, Hu Y, Slingluff CL Jr.

Semin Oncol. 2015 Aug;42(4):549-61. doi: 10.1053/j.seminoncol.2015.05.006. Epub 2015 Jun 3. Review.

PMID:
26320060
13.

Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.

Riabov V, Tretyakova I, Alexander RB, Pushko P, Klyushnenkova EN.

Vaccine. 2015 Oct 5;33(41):5386-95. doi: 10.1016/j.vaccine.2015.08.062. Epub 2015 Aug 28.

PMID:
26319744
14.
15.

Development of PROSTVAC immunotherapy in prostate cancer.

Singh P, Pal SK, Alex A, Agarwal N.

Future Oncol. 2015;11(15):2137-48. doi: 10.2217/fon.15.120.

PMID:
26235179
16.

Therapeutic cancer vaccines.

Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH.

J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. Review.

PMID:
26214521
17.

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, van den Eertwegh AJ, de Gruijl TD.

J Immunother Cancer. 2014 Sep 16;2:31. doi: 10.1186/s40425-014-0031-3. eCollection 2014.

18.

Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?

Johnson P, Greiner W, Al-Dakkak I, Wagner S.

Biomed Res Int. 2015;2015:865101. doi: 10.1155/2015/865101. Epub 2015 Jun 16. Review.

19.

Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer.

Silvestri I, Cattarino S, Aglianò AM, Collalti G, Sciarra A.

Biomed Res Int. 2015;2015:794968. doi: 10.1155/2015/794968. Epub 2015 Jun 16. Review.

20.

DNA vaccination for prostate cancer: key concepts and considerations.

Cole G, McCaffrey J, Ali AA, McCarthy HO.

Cancer Nanotechnol. 2015;6(1):2. Epub 2015 Jul 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk